JP2017515836A5 - - Google Patents

Download PDF

Info

Publication number
JP2017515836A5
JP2017515836A5 JP2016567364A JP2016567364A JP2017515836A5 JP 2017515836 A5 JP2017515836 A5 JP 2017515836A5 JP 2016567364 A JP2016567364 A JP 2016567364A JP 2016567364 A JP2016567364 A JP 2016567364A JP 2017515836 A5 JP2017515836 A5 JP 2017515836A5
Authority
JP
Japan
Prior art keywords
amino
methyl
phenyl
pyrazolo
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016567364A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017515836A (ja
JP6663857B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2015/053174 external-priority patent/WO2015173683A1/en
Publication of JP2017515836A publication Critical patent/JP2017515836A/ja
Publication of JP2017515836A5 publication Critical patent/JP2017515836A5/ja
Application granted granted Critical
Publication of JP6663857B2 publication Critical patent/JP6663857B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016567364A 2014-05-14 2015-04-30 ピラゾロピリジンおよびピラゾロピリミジン Expired - Fee Related JP6663857B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461993138P 2014-05-14 2014-05-14
US61/993,138 2014-05-14
PCT/IB2015/053174 WO2015173683A1 (en) 2014-05-14 2015-04-30 Pyrazolopyridines and pyrazolopyrimidines

Publications (3)

Publication Number Publication Date
JP2017515836A JP2017515836A (ja) 2017-06-15
JP2017515836A5 true JP2017515836A5 (enExample) 2018-05-31
JP6663857B2 JP6663857B2 (ja) 2020-03-13

Family

ID=53264695

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016567364A Expired - Fee Related JP6663857B2 (ja) 2014-05-14 2015-04-30 ピラゾロピリジンおよびピラゾロピリミジン

Country Status (29)

Country Link
US (2) US9518052B2 (enExample)
EP (1) EP3143021B1 (enExample)
JP (1) JP6663857B2 (enExample)
KR (1) KR20170002623A (enExample)
CN (1) CN106459048A (enExample)
AP (1) AP2016009562A0 (enExample)
AR (1) AR100438A1 (enExample)
AU (1) AU2015260905A1 (enExample)
CA (1) CA2948587C (enExample)
CL (1) CL2016002888A1 (enExample)
CR (1) CR20160525A (enExample)
CU (1) CU20160167A7 (enExample)
DO (1) DOP2016000298A (enExample)
EA (1) EA201650029A1 (enExample)
EC (1) ECSP16087271A (enExample)
ES (1) ES2737696T3 (enExample)
GE (2) GEAP201814322A (enExample)
IL (1) IL248970A0 (enExample)
MD (1) MD20160121A2 (enExample)
MX (1) MX2016014878A (enExample)
NI (1) NI201600170A (enExample)
PE (1) PE20161475A1 (enExample)
PH (1) PH12016502228A1 (enExample)
SG (1) SG11201609139WA (enExample)
SV (1) SV2016005318A (enExample)
TN (1) TN2016000503A1 (enExample)
TW (1) TWI591067B (enExample)
UY (1) UY36121A (enExample)
WO (1) WO2015173683A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2948587C (en) 2014-05-14 2018-07-17 Pfizer Inc. Pyrazolopyridines and pyrazolopyrimidines
US9403810B2 (en) 2014-05-14 2016-08-02 Novartis Ag Carboxamide derivatives
US10100049B2 (en) 2015-11-03 2018-10-16 Theravance Biopharma R&D Ip, Llc JAK kinase inhibitor compounds for treatment of respiratory disease
US10556901B2 (en) 2015-11-03 2020-02-11 Topivert Pharma Limited 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as Janus kinase inhibitors
PL3712152T3 (pl) 2015-11-03 2021-08-02 Topivert Pharma Limited Pochodne 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pirydyny i 1,4,5,6,7,8-heksahydroimidazo[4,5-d]azepiny jako inhibitory kinaz janusowych
EP3592743A1 (en) 2017-03-09 2020-01-15 Theravance Biopharma R&D IP, LLC Fused imidazo-piperidine jak inhibitors
AR111495A1 (es) 2017-05-01 2019-07-17 Theravance Biopharma R&D Ip Llc Compuestos de imidazo-piperidina fusionada como inhibidores de jak
WO2018204233A1 (en) 2017-05-01 2018-11-08 Theravance Biopharma R&D Ip, Llc Methods of treatment using a jak inhibitor compound
CN110603255B (zh) 2017-05-01 2023-02-10 施万生物制药研发Ip有限责任公司 Jak抑制剂化合物的结晶型式
BR112020002265A2 (pt) 2017-08-01 2020-07-28 Theravance Biopharma R&D Ip, Llc compostos pirazólicos e triazólicos bicíclicos como inibidores de jak quiinase
CN119119039A (zh) 2017-11-03 2024-12-13 阿克拉瑞斯治疗股份有限公司 被取代的吡咯并吡啶jak抑制剂及其制造方法和使用方法
US11021482B2 (en) 2018-08-10 2021-06-01 Adaris Therapeutics, Inc. Pyrrolopyrimidine ITK inhibitors
CN110833555B (zh) * 2018-08-15 2023-03-24 广西梧州制药(集团)股份有限公司 吡唑并嘧啶衍生物在治疗溃疡性结肠炎的用途
EA202190686A1 (ru) 2018-09-04 2021-07-23 ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи 5-7-членные гетероциклические амиды в качестве ингибиторов jak
CN112638902A (zh) 2018-09-04 2021-04-09 施万生物制药研发Ip有限责任公司 用于制备jak抑制剂的方法及其中间体
JP7324836B2 (ja) 2018-09-04 2023-08-10 セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー Jak阻害剤としてのジメチルアミノアゼチジンアミド
CN112955451A (zh) 2018-10-29 2021-06-11 施万生物制药研发Ip有限责任公司 作为jak抑制剂的2-氮杂双环已烷化合物
US10851102B2 (en) 2019-01-23 2020-12-01 Theravance Biopharma R&D Ip, Llc Imidazole and triazole containing bicyclic compounds as JAK inhibitors
CN114075199A (zh) * 2020-08-14 2022-02-22 河南迈英诺医药科技有限公司 Jak抑制剂化合物及其用途
CN114075200A (zh) * 2020-08-14 2022-02-22 河南迈英诺医药科技有限公司 用于治疗重症肺炎的jak抑制剂化合物
JP7514025B2 (ja) * 2019-02-25 2024-07-10 ホーナン メディノ ファーマシューティカル テクノロジー カンパニー リミテッド Jak阻害剤化合物及びその使用
EP3962897A4 (en) 2019-05-02 2022-12-14 Aclaris Therapeutics, Inc. SUBSTITUTED PYRROLOPYRIDINES AS JAK INHIBITORS
WO2021022178A1 (en) * 2019-07-31 2021-02-04 Aclaris Therapeutics, Inc. Substituted sulfonamide pyrrolopyridines as jak inhibitors
JP7580136B2 (ja) * 2019-12-30 2024-11-11 路良 Jak阻害剤化合物及びその使用
PH12022551623A1 (en) 2020-01-13 2023-11-29 Verge Analytics Inc Substituted pyrazolo-pyrimidines and uses thereof
CN113101975B (zh) * 2020-01-13 2022-04-22 万华化学集团股份有限公司 一种多膦配体催化剂体系及其在乙烯齐聚反应的应用
TW202144343A (zh) 2020-03-02 2021-12-01 美商施萬生物製藥研發 Ip有限責任公司 Jak抑制劑化合物之結晶水合物
CN111548269B (zh) * 2020-04-29 2023-10-27 兰州大学 一种二芳基甲烷结构化合物的制备方法
GB202010408D0 (en) * 2020-07-07 2020-08-19 Reviral Ltd Pharmaceutical compounds
CA3192236A1 (en) 2020-09-10 2022-03-17 Tony Lahoutte Antibody fragment against fap
EP4359402A1 (en) 2021-06-25 2024-05-01 Theravance Biopharma R&D IP, LLC Imidazolo indazole compounds as jak inhibitors
CN115557947B (zh) * 2021-07-02 2024-04-02 成都百裕制药股份有限公司 吡唑并[4,3-c]吡啶衍生物及其在医药上的应用
CN113480543B (zh) * 2021-07-07 2022-05-17 无锡市第二人民医院 2,6,8-多取代咪唑并[1,2-a]吡嗪及其合成方法和应用
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
WO2023213801A1 (en) 2022-05-02 2023-11-09 Precirix N.V. Pre-targeting
WO2025217560A1 (en) * 2024-04-12 2025-10-16 Theravance Biopharma R&D Ip, Llc Triazolo indazole compounds as jak inhibitors

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US20030139427A1 (en) * 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
EP1562898A1 (en) 2002-11-19 2005-08-17 Takeda Pharmaceutical Company Limited Indole derivatives as somatostatin agonists or antagonists
US20080234262A1 (en) * 2007-03-21 2008-09-25 Wyeth Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors
JP4782239B2 (ja) 2007-04-18 2011-09-28 ファイザー・プロダクツ・インク 異常細胞増殖治療のためのスルホニルアミド誘導体
CA2702838A1 (en) * 2007-10-16 2009-04-23 Wyeth Llc Thienopyrimidine and pyrazolopyrimidine compounds and their use as mtor kinase and pi3 kinase inhibitors
JP2011503103A (ja) * 2007-11-07 2011-01-27 フォールドアールエックス ファーマシューティカルズ インコーポレーティッド タンパク質輸送の調節方法
WO2009070524A1 (en) * 2007-11-27 2009-06-04 Wyeth Pyrrolo[3,2-d]pyrimidine compounds and their use as pi3 kinase and mtor kinase inhibitors
KR20100113567A (ko) * 2008-01-15 2010-10-21 와이어쓰 엘엘씨 3H-[1,2,3]트라이아졸로[4,5-D]피리미딘 화합물, mTOR 카이네이즈 및 PI3 카이네이즈 억제제로서의 이의 용도 및 합성
ES2494365T3 (es) * 2008-01-30 2014-09-15 Genentech, Inc. Compuestos de pirazolopirimidina que inhiben PI3K y métodos de uso
EP2280946B1 (en) * 2008-06-05 2016-02-10 Glaxo Group Limited 4-carboxamide indazole derivatives useful as inhibitors of p13-kinases
WO2009153261A1 (en) * 2008-06-18 2009-12-23 Solvay Pharmaceuticals Gmbh HYDROXYPHENYL-SUBSTITUTED PYRROLO[2,3d]PYRIMIDINE DERIVATIVES, PROCESSES AND INTERMEDIATE PRODUCTS FOR THEIR PREPARATION AND MEDICAMENTS CONTAINING THESE COMPOUNDS
JPWO2010058846A1 (ja) 2008-11-21 2012-04-19 アステラス製薬株式会社 4,6−ジアミノニコチンアミド化合物
JP5732036B2 (ja) * 2009-03-19 2015-06-10 メディカル リサーチ カウンシル テクノロジーMedical Research Council Technology 化合物
WO2012045195A1 (en) 2010-10-09 2012-04-12 Abbott Laboratories Pyrrolopyrimidines as fak and alk inhibiters for treatment of cancers and other diseases
US8575336B2 (en) * 2011-07-27 2013-11-05 Pfizer Limited Indazoles
CA2948587C (en) 2014-05-14 2018-07-17 Pfizer Inc. Pyrazolopyridines and pyrazolopyrimidines

Similar Documents

Publication Publication Date Title
JP2017515836A5 (enExample)
JP2013523710A5 (enExample)
ES2642586T3 (es) Compuestos heterocíclicos condensados como moduladores de canales iónicos
JP4814783B2 (ja) ピラゾロピリジン誘導体
RU2018138050A (ru) Производные тиазолопиридина как агонисты gpr119
TWI756482B (zh) 治療活性化合物及其使用方法
EP1326856B1 (en) Pyridine derivatives with ikb-kinase (ikk-beta) inhibiting activity
RU2018123825A (ru) Соединения и способы для модуляции киназ, и показания для этого
JP2018534326A5 (enExample)
HRP20171913T1 (hr) Aminopirimidinilni spojevi kao inhibitori jak
JP2019504009A5 (enExample)
RU2018138047A (ru) Гетероциклические вещества - агонисты gpr119
HRP20212000T1 (hr) Aminotriazolopiridini kao inhibitori kinaze
TWI455715B (zh) 4-(4-氰基-2-硫基芳基)二氫嘧啶酮類及其用途
JP2015514794A5 (enExample)
JP2017500362A5 (enExample)
JP2013544840A5 (enExample)
JP2013502429A5 (enExample)
AU2011272800A1 (en) sGC stimulators
JP2012532931A5 (enExample)
JP2013544256A5 (enExample)
JP2014527511A5 (enExample)
JP2011518219A5 (enExample)
JP2019529443A5 (enExample)
JP2016514124A (ja) 変異idhの阻害薬としての3−ピリミジン−4−イル−オキサゾリジン−2−オン